BlackRock Inc. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 27 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2022$3,515,000
+22.6%
3,847,000
+26.3%
0.00%
Q4 2021$2,868,000
+5.0%
3,045,0000.0%0.00%
Q3 2021$2,731,000
-92.5%
3,045,000
-92.6%
0.00%
-100.0%
Q2 2021$36,647,000
+2024.5%
40,877,000
+1828.2%
0.00%
Q1 2021$1,725,000
-5.6%
2,120,000
-10.5%
0.00%
Q4 2020$1,827,000
+65.9%
2,370,000
+73.0%
0.00%
Q3 2020$1,101,000
+6.8%
1,370,0000.0%0.00%
Q2 2020$1,031,000
-5.9%
1,370,0000.0%0.00%
Q1 2020$1,096,000
-26.0%
1,370,000
-6.8%
0.00%
Q4 2019$1,482,000
+9.8%
1,470,000
-6.4%
0.00%
Q3 2019$1,350,000
+23.6%
1,570,000
+28.2%
0.00%
Q2 2019$1,092,000
-9.9%
1,225,0000.0%0.00%
Q1 2019$1,212,000
+16.9%
1,225,000
+8.9%
0.00%
Q4 2018$1,037,000
+2.6%
1,125,000
+12.5%
0.00%
Q3 2018$1,011,000
+53.9%
1,000,000
+33.3%
0.00%
Q2 2018$657,000
-38.1%
750,000
-43.4%
0.00%
Q1 2018$1,062,000
-5.1%
1,325,000
-5.9%
0.00%
Q4 2017$1,119,000
+2.8%
1,408,0000.0%0.00%
Q3 2017$1,088,000
+76.6%
1,408,000
+122.4%
0.00%
Q2 2017$616,000
+39.1%
633,000
+33.3%
0.00%
Q1 2017$443,000475,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2021
NameSharesValueWeighting ↓
Silver Point Capital L.P. 57,420,000$44,527,0005.17%
Birch Grove Capital LP 10,003,000$7,934,0004.14%
PenderFund Capital Management Ltd. 9,605,000$9,491,0002.41%
Context Capital Management, LLC 9,887,000$7,671,0001.05%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$45,738,0000.90%
DeepCurrents Investment Group LLC 35,892,000$27,953,0000.74%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 22,977,000$18,267,0000.70%
WHITEBOX ADVISORS LLC 23,150,000$17,847,0000.56%
ADVENT CAPITAL MANAGEMENT /DE/ 27,397,000$21,720,0000.46%
OAKTREE CAPITAL MANAGEMENT LP 19,435,000$15,079,0000.26%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders